Eli Lilly Set to Back Aktis Oncology’s Upsized $318 Million IPO

Eli Lilly Set to Back Aktis Oncology’s Upsized $318 Million IPO


Aktis Oncology Inc. increased the size of its initial public offering by 50%, and drew interest from Eli Lilly & Co. for $100 million of shares in the listing.

Sign in to read the full article.

Sign in with Google

Settings

Appearance
API Keys